

WOAH Reference Laboratory Reports Activities 2023

Activities in 2023

This report has been submitted : 6 juin 2024 14:21

Laboratory Information

Name of disease (or topic) for which you are a designated WOAHO Reference Laboratory:	Turkey Rhinotracheitis
Address of laboratory:	Anses, Laboratoire de Ploufragan-Plouzané-Niort, BP53, 41 rue de Beaucemaine, 22440 Ploufragan, FRANCE
Tel.:	+33296016222
E-mail address:	nicolas.eterradosi@anses.fr
Website:	https://www.anses.fr/fr/content/laboratoire-de-ploufragan-plouzan%C3%A9-niort
Name (including Title) of Head of Laboratory (Responsible Official):	Dr Nicolas Eterradosi
Name (including Title and Position) of WOAHO Reference Expert:	Dr Nicolas Eterradosi, Head of laboratory
Which of the following defines your laboratory? Check all that apply:	Governmental

TOR1: DIAGNOSTIC METHODS

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in WOAHO Manual (Yes/No)	Total number of test performed last year	
		Nationally	Internationally
Indirect diagnostic tests			
ELISA for the detection of AMPV antibodies		1604	0
Direct diagnostic tests			
detection and quantification of AMPV genome by rRT-PCR		1226	0

TOR2: REFERENCE MATERIAL

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by WOAHO?

No

3. Did your laboratory supply standard reference reagents (nonWOAH-approved) and/or other diagnostic reagents to WOAHO Members?

Yes

TYPE OF REAGENT AVAILABLE	RELATED DIAGNOSTIC TEST	PRODUCED/ PROVIDE	AMOUNT SUPPLIED NATIONALLY (ML, MG)	AMOUNT SUPPLIED INTERNATIONALLY (ML, MG)	NO. OF RECIPIENT WOAHO MEMBER COUNTRIES	COUNTRY OF RECIPIENTS
Antigen	ELISA	produced and provided	12 ml	0 ml	1	FRANCE,
Monospecific Antisera	ELISA, VN, IIF	Produced and provided	2 ml	0 ml	1	FRANCE,

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to WOAHA Members?

No

TOR3: NEW PROCEDURES

6. Did your laboratory develop new diagnostic methods for the designated pathogen or disease?

No

7. Did your laboratory validate diagnostic methods according to WOAHA Standards for the designated pathogen or disease?

No

8. Did your laboratory develop new vaccines for the designated pathogen or disease?

No

9. Did your laboratory validate vaccines according to WOAHA Standards for the designated pathogen or disease?

No

TOR4: DIAGNOSTIC TESTING FACILITIES

10. Did your laboratory carry out diagnostic testing for other WOAHA Members?

No

11. Did your laboratory provide expert advice in technical consultancies on the request of an WOAHA Member?

No

TOR5: COLLABORATIVE SCIENTIFIC AND TECHNICAL STUDIES

12. Did your laboratory participate in international scientific studies in collaboration with WOAHA Members other than the own?

No

13. In exercising your activities, have you identified any regulatory research needs* relevant for WOAHA?

No

TOR6: EPIZOOLOGICAL DATA

14. Did your Laboratory collect epidemiological data relevant to international disease control?

Yes

IF THE ANSWER IS YES, PLEASE PROVIDE DETAILS OF THE DATA COLLECTED:

The laboratory took advantage of the collection of fecal or respiratory samples from wild birds in France for 1 year during a project on another pathogen to look for the presence of AMPV traces. No AMPV could be detected in the samples from those wild birds (results to be published within report of a wider study).

15. Did your laboratory disseminate epidemiological data that had been processed and analysed?

No

16. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category and list the details in the box)

a) Articles published in peer-reviewed journals:

1

Lupini C, Tucciarone CM, Mescolini G, Quaglia G, Graziosi G, Turblin V, et al. Longitudinal Survey on aMPV Circulation in French Broiler Flocks following Different Vaccination Strategies. *Animals*. 2023;13(1):57.

b) International conferences:

c) National conferences:

d) Other (Provide website address or link to appropriate information):

Contribution to WOAHA expert group on turkey rhinotracheitis / avian metapneumovirus case definition

TOR7: SCIENTIFIC AND TECHNICAL TRAINING

17. Did your laboratory provide scientific and technical training to laboratory personnel from other WOAHA Members?

No

TOR8: QUALITY ASSURANCE

18. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)	
ISO 17025	Compliance certificate ISO 17025 2023-2024.pdf	Compliance certificate ISO 17025 2023-2024.pdf

19. Is your quality management system accredited?

No

20. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

The laboratory quality management system and procedures comply with nationally applicable regulations and cover biorisk (biosafety and biosecurity) evaluation and management, in line with recommendations of chapter 1.1.4 of OIE Manual

TOR9: SCIENTIFIC MEETINGS

21. Did your laboratory organise scientific meetings related to the pathogen in question on behalf of WOAHA?

No

22. Did your laboratory participate in scientific meetings related to the pathogen in question on behalf of WOAHA?

Yes

Title of event	Date (mm/yy)	Location	Role (speaker, presenting poster, short communications)	Title of the work presented
Online meetings of working group on turkey rhinotracheitis / avian metapneumovirus infection case definition	2023-12-08	Online	participant	Reply to questions on case definition produced previously

TOR10: NETWORK WITH WOAHA REFERENCE LABORATORIES

23. Did your laboratory exchange information with other WOAHA Reference Laboratories designated for the same pathogen or disease?

Not applicable (only WOAHA Reference Laboratory designated for the disease)

24. Do you network (collaborate or share information) with other WOAHA Reference Laboratories designated for the same pathogen?

Not applicable (Only WOAHA Reference Laboratory designated for the disease)

25. Did you organise or participate in inter-laboratory proficiency tests with WOAHA Reference Laboratories designated for the same pathogen?

Not applicable (Only WOAHA Reference Laboratory designated for the disease)

26. Did your laboratory collaborate with other WOAHA Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the

pathogen of interest?

Not applicable (Only WOA Reference Laboratory designated for the disease)

TOR11: OTHER INTERLABORATORY PROFICIENCY TESTING

27. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than WOA Reference Laboratories for the same pathogen?

No

TOR12: EXPERT CONSULTANTS

28. Did your laboratory place expert consultants at the disposal of WOA?

Yes

KIND OF CONSULTANCY	Location	SUBJECT (FACULTATIVE)
Working group on turkey rhinotracheitis / avian metapneumovirus infections case definition	Online	Responses to questions arising from case definition produced previously

29. Additional comments regarding your report:

Yes

Human resource issues in WOA AMPV reference laboratory (two senior scientists missing in 2023) interfered with AMPV reference and research activities. New organization defined, recruitments in progress and new projects launched for 2024.